Selected stock price target: $40, which sits just above LEGN’s 52-week high of $38.35 and implies nearly double the recent price near $20.60. Strongest bullish factors: accelerating Carvykti sales, the first quarter of company-wide profitability, and promising early in vivo CAR-T data.

OBX traded down -15.25% to $27.88 during regular hours Wednesday, following a prior-session close at $32.90 (-6.00%). The decline extends a volatile post-debut stretch after the Aug 4 reverse merger with Galera and the $350 million private placement.

Selected price target: $2.00 per share, roughly 160% above Inovio's recent trading level near $0.77. Strongest bullish factor: The FDA is reviewing Inovio's lead DNA medicine candidate, INO-3107, with a PDUFA target action date of October 30, 2026.

Inovio Pharmaceuticals (NASDAQ: INO) is scheduled to report second-quarter 2026 results after the U.S. market close on August 12, 2026, followed by a conference call at 4:30 p.m. Eastern Time. The consensus estimate calls for a net loss of $0.24 per share, narrower than the $0.61 loss reported in the prior-year quarter.

INO shares fell approximately 33.5% from a closing price of $1.16 on July 13, 2026, to an intraday price near $0.77 on August 12, 2026. The sharpest sell-off followed INOVIO's late-July pricing of a $20 million public offering of common stock and warrants, which triggered immediate dilution concerns.

Multiple late-stage oncology readouts, including five-year Phase 2 melanoma data and Phase 3 adjuvant melanoma results for intismeran, are expected in 2026 and could shape sentiment around the mRNA platform's expansion into cancer therapies. Potential regulatory approvals for mNEXSPIKE in select markets, flu vaccine, and flu + COVID-19 combination candidates position the company for portfolio diversification beyond its established COVID-19 franchise.

Selected price target: $7.00 per share, the most widely cited lower-bound analyst target and a round-number level sitting just above the stock's 52-week high of $6.55. Starting point: SANA closed the most recent regular session near $3.79, meaning a move to $7 would require roughly 85% upside.

Selected price target: $60, approximately 47% above the recent $40.91 close and essentially in line with the consensus analyst price target of about $60. Strongest bullish factor: A late-stage pipeline led by DT120 in depression and anxiety, supported by U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation for generalized anxiety disorder (GAD).

The selected price target is $7 , roughly 81% above the latest close of $3.87 and about 35% above the 52-week high of $5.17. Wall Street support is a key bullish factor: the low end of current analyst price targets clusters near $6 to $7, with consensus estimates well above that level.

Completion of dosing in the REVEAL pivotal trial for TSHA-102 positions the company for key 6-month interim data and FDA feedback expected in the first half of 2027, potentially informing a Biologics License Application (BLA) pathway. Strong analyst consensus with a Buy rating from multiple firms and an average price target around $12.50 to $13.25 reflects optimism around clinical execution in Rett syndrome.

Price target: $10 represents the lowest analyst consensus target for TSHA and a psychologically significant round number, implying roughly 50% upside from recent trading levels around $6.66. Strongest bullish factors: Exceptional clinical data from the REVEAL pivotal trial showing 100% of Rett syndrome patients gained developmental milestones, multiple FDA expedited designations including Breakthrough Therapy status, and a cash runway extending into 2028.

Price target in focus: $22 per share, representing the lowest Wall Street analyst target and roughly 75% upside from recent trading levels near $12.59. Strongest bullish catalyst: TONMYA, the first FDA-approved fibromyalgia treatment in over 15 years, posted $11 million in Q2 2026 net sales — nearly tripling quarter-over-quarter — with prescriptions doubling and refills surging 207%.

Price Target: The $1.00 level represents the sole published analyst price target for NWBO, implying an upside of roughly 400–500% from its recent trading range near $0.18–$0.23. Strongest Bullish Factor: A potential regulatory approval of DCVax-L by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) would be a transformative catalyst, validating the company's dendritic cell immunotherapy platform.

NWBO shares declined approximately 12.5% over the 30-day period ending early August 2026, falling from around $0.18 to roughly $0.16. The stock touched a 52-week low of $0.1411 on July 16, marking the lowest point in more than a year for the clinical-stage biotech.

TENX crashed -88.10% from its previous close of $13.44 to ~$1.60, with the collapse beginning in premarket trading and extending into the regular session. The primary catalyst: Tenax announced its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) for PH-HFpEF failed to meet both its primary endpoint on 6-minute walk distance and its key secondary endpoint on symptom improvement.

SION collapsed approximately -91.77% in pre-market trading Monday, plunging from Friday's close of $51.04 to around $4.20 during the regular session. The crash was triggered by the company's Q2 pipeline update, which revealed primary endpoint data for its cystic fibrosis program that fell dramatically short of investor expectations.

Price target in focus: $400 represents a psychological milestone approximately 36% above LGND's recent closing price of $293.15 and well beyond its 52-week high of $326.63. Strongest bullish factors: The completed XOMA Royalty acquisition doubles Ligand's portfolio to over 200 assets, recent quarterly results handily beat expectations, and the royalty-driven business model generates high-margin recurring revenue with substantial operating leverage.

ARDX plunged -16.22% to $4.08 after Q2 2026 results released post-close Wednesday missed estimates: EPS of -$0.07 vs. -$0.04 consensus and revenue of $120.9M vs. $125.1M expected. The primary catalyst was a ~$60M cut to 2026 IBSRELA revenue guidance, now $350M–$370M, as tighter payer prior authorizations and step edits slowed new patient starts despite record underlying demand.

Agenus (AGEN) shares surged approximately 130% over the past 30 days, propelled by an oversubscribed private placement of up to $340 million and a strategic pipeline pivot toward a registrational Phase 3 trial in MSS colon cancer. The company announced on July 13, 2026 that it would discontinue financial support for its BATTMAN metastatic colorectal cancer study and redirect resources to the ROBBIN trial, targeting a $7 billion-plus U.S. addressable market.

TYRA shares dropped -17.15% during regular trading hours, falling from a prior close of $32.53 to $26.95, driven by a dual negative catalyst of disappointing Q2 earnings and a delayed clinical readout. The company reported a Q2 GAAP EPS loss of -$0.69, missing consensus estimates of -$0.64, while net loss widened to $45.6 million versus $28.1 million in the year-ago quarter.